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A B S T R A C T   
Inflammatory bowel disease (IBD) is a chronic and idiopathic inflammatory disorder affecting the gastrointes-
tinal tract. The pharmacological treatments used currently for its treatment lack efficacy, so new therapeutic 
strategies should be developed. In this context, flavonoids loaded in biopolymeric nanoparticles can be 
considered as novel promising candidates. The aim of the present study was to evaluate the intestinal anti- 
inflammatory effects of quercetin when is administered loaded in silk fibroin nanoparticles (QSFN) in the 
dextran sulphate sodium experimental model of mouse colitis, which displays some similarities to human IBD. 
Previously characterized quercetin-loaded silk fibroin nanoparticles (QSFN). QSFN showed a reversible aggre-
gation profile induced by the acidification of the solution but did not affect the loaded quercetin. Daily 
administration of QSFN significantly reduced disease activity index values compared to the control colitic group. 
This beneficial effect was not only corroborated by the histological examination of the colonic specimens but also 
the improvement of the colonic expression of the different proinflammatory cytokines (Tnf-α, Il-1β, Il-6, Mcp-1, 
Icam-1, Nlrp3 and iNOS). Therefore, these data suggest that QSFN could be a promising alternative to current 
treatments as a drug delivery system for IBD treatment.   
1. Introduction 
Inflammatory bowel disease (IBD) comprises chronic and idiopathic 
inflammatory disorders affecting the gastrointestinal tract, mainly ul-
cerative colitis and Crohn’s disease (Sairenji et al., 2017). Its prevalence 
in the general population is up to 0.3%, but it is increasing and has 
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become a worldwide problem (Ng et al., 2017). Although the aetiology 
is unclear, genetic and environmental factors are involved, including 
alterations of the intestinal microbiota composition and/or function 
(termed as dysbiosis), as well as the immune response (de Souza et al., 
2017). IBD is characterized by an up-regulation of different proin-
flammatory mediators, such as cytokines, nitrogen and oxide reactive 
species, eicosanoids and platelet-activating factor, together with an 
impairment of the intestinal epithelial integrity, thus leading to a 
chronic inflammation of the gut (Vezza et al., 2016). The current 
pharmacological strategies for the management of IBD, such as amino-
salicylates, glucocorticoids, immunomodulators or biologicals, like anti- 
tumour necrosis factor α (TNF-α) antibodies (Seyedian et al., 2019), fail 
to induce and maintain remission in some patients and are associated 
with a high incidence of adverse effects, which can limit its adminis-
tration (Abraham and Quigley, 2020). In consequence, there is a need 
for safer and more effective treatments that could complement or sub-
stitute the current available drugs. In this context, flavonoids, low- 
molecular-weight polyphenolic phytochemicals found in vegetables 
and fruits, can be considered as promising candidates (Filipe-Ribeiro 
et al., 2018). They have extensively shown anti-inflammatory, antioxi-
dant and immunomodulatory properties, without presenting important 
toxic or side effects (Panche et al., 2016). After ingestion, flavonoids can 
be absorbed or directly act on gut epithelial, endocrine and immune 
cells, strengthening the intestinal barrier integrity and modulating the 
immune response. Moreover, they can also suffer biotransformation 
either by intestinal epithelial cells or the microbiota, and their metab-
olites can also exert further beneficial biological actions (Oteiza et al., 
2018). 
Among dietary flavonoids, quercetin is the most ubiquitous, being 
largely present in vegetables, fruits, tea, wine and olive oil (Lakhanpal, 
2007). It is mainly found as glycosylated forms, such as quercitrin or 
rutin (Xiao and Lee, 2018). Quercetin has been reported for its anti- 
inflammatory, anti-oxidative, antihypertensive and anti-thrombotic 
properties for the treatment of different conditions, including cardio-
vascular diseases, obesity, diabetes and even cancer (Batiha et al., 
2020). When considering the impact of quercetin on intestinal inflam-
mation, the studies reveal inconsistent results. Kwon et al. (2005) failed 
to observe beneficial effects in the dextran sulphate sodium (DSS) model 
of mouse colitis while more recent studies have reported intestinal anti- 
inflammatory effects of quercetin in the same experimental model (Dong 
et al., 2020; Ju et al., 2018). However, quercetin glycosides, including 
quercitrin or rutin, have shown intestinal anti-inflammatory properties 
in various experimental models of colitis (Camuesco et al., 2004; 
Comalada et al., 2005; Kwon et al., 2005), being their effects attributed 
to quercetin, which is released after hydrolysis in the colon (Comalada 
et al., 2005). 
Therefore, the fact that quercetin can be absorbed in the stomach and 
small intestine, or suffer intense degradation and rapid metabolism, may 
prevent its access to the colon at effective concentrations to display local 
anti-inflammatory and antioxidant effects, thus limiting its potential use 
for the management of these intestinal conditions (Berkel KaŞIkci and 
Bağdatlıoğlu, 2016; Crespy et al., 2002). Nevertheless, different quer-
cetin delivery systems have been developed, in order to avoid extraction 
procedures and enhance their pharmacokinetic properties (Cai et al., 
2013). For instance, quercetin-loaded microcapsules have been reported 
to ameliorate experimental colitis, showing higher efficacy than quer-
cetin (Guazelli et al., 2013). It is acknowledged that nanoparticles have 
the potential to improve the stability and solubility of encapsulated 
cargos, facilitate the crossing through biological barriers and prolong 
circulation times. Thus, they are able to increase safety and efficacy, and 
reduce limitations of free drugs (Blanco et al., 2015; Kou et al., 2018; 
Davoudi, et al 2021). It is important to note that nanoparticles, increase 
the contact surface between the particle and the surrounding area, thus 
increasing its absorption and effectiveness (Khadka et al., 2014). Indeed, 
mucosal inflammation is closely related to loss of the inner adherent and 
the outer mobile mucus-gel layers, and impairment of the epithelial 
barrier integrity due to enterocyte damage. These alterations facilitate 
accumulation and uptake of nanoparticles by both enterocytes and 
macrophages, and increase exposure of the inflammatory receptors to 
nanoparticles (Hua et al., 2015). Silk nanoparticles have emerged, 
among other biopolymeric nanoparticles, as good candidates for drug 
delivery in medicinal applications because they are constituted by 
highly versatile, non-toxic, biocompatible and biodegradable proteins 
(Crivelli et al., 2018; Pham and Tiyaboonchai, 2020; Zhao et al., 2015; 
Lamboni et al., 2015; Tomeh et al., 2019; Ma et al., 2020). Silk fibroin 
nanoparticles have already been used in nanomedicine as a bioactive 
reversible carrier of macromolecules (Hofmann et al., 2006; Liu et al., 
2017; Mottaghitalab et al., 2015) and small polyphenolic biomolecules 
such as resveratrol (Lozano-Pérez et al., 2014) or curcumin (Crivelli 
et al., 2019; Montalbán et al., 2018), among others. In a previous study 
our group demonstrated quercetin-loading efficiency of silk fibroin 
nanoparticles, which improved the stability and bioavailability of the 
compound (Lozano-Pérez et al., 2017). Then, <40% of the loaded 
quercetin was released in the gastrointestinal tract, where it could exert 
local beneficial effects, while the remaining could reach the colon, un-
modified, which augments its anti-inflammatory effect in the damaged 
areas. Besides, silk fibroin nanoparticles should not be considered as 
mere inert carriers since they have also been reported to have intestinal 
anti-inflammatory properties in experimental models of colitis (Mon-
talbán et al., 2018) and periodontitis in rats (Gimenez-Siurana et al., 
2020). Moreover, a recent work has proven safety for oral use of silk 
derived from Bombyx mori cocoons at doses up to 500 mg/kg body 
weight/day, assessing toxicological and food allergy concerns, using 
well-established in vitro and in vivo models, and bioinformatics evalua-
tion methods (Yigit et al., 2021). 
We, therefore, hypothesized that silk fibroin nanoparticles would 
effectively deliver quercetin to the damaged intestinal cells improving 
quercetin intestinal wound healing capacity. 
Thus, the aim of the present study was to evaluate the intestinal anti- 
inflammatory effects of quercetin when it is administered loaded in silk 
fibroin nanoparticles in the DSS experimental model of mouse colitis, 
which resembles human IBD considering its pathogenesis and thera-
peutic response (Yigit et al., 2021). 
2. Materials and methods 
2.1. Reagents 
Silk fibroin (SF) was obtained, as previously described by our group 
(Lozano-Pérez et al., 2017), from cocoons of white silkworm (Bombyx 
mori) reared in the sericulture facilities of IMIDA (Murcia, Spain) and fed 
a diet of fresh Morus alba L. leaves. Quercetin and all chemicals were 
purchased from Sigma Aldrich Química, S.A. (Madrid, Spain), unless 
otherwise stated. Silk fibroin nanoparticles (SFNs) were prepared 
following the methodology described before (Lozano-Pérez et al., 2017), 
according to an adapted version of the method reported by Zhang et al. 
(Zhang et al., 2007). Ultrapure water (18.2 MΩ⋅cm− 1) produced by an 
ELGA Purelab Flex 2 (Veolia, High Wycombe, UK) was used throughout. 
2.2. Preparation of the quercetin loaded silk fibroin nanoparticles 
Quercetin-loaded silk fibroin nanoparticles (QSFN) for the in vivo 
assays were prepared in one batch as described before by a simple in-
cubation of quercetin (Q) and SFNs at Q/SFN 1:25 (w/w) ratio, which 
produced the highest drug loading content according to previous results 
(Lozano-Pérez et al., 2017). Briefly, 40 mL of a solution of quercetin 0.5 
mM in ethanol (6.4 mg) was mixed with an aqueous suspension of SFNs 
at 10 mg/mL (160 mg) and stirred for 3 h protected from light. QSFNs 
were recovered by centrifugation, washed with ultra-pure water (3x), 
and finally freeze-dried. QSFNs were obtained as a light green dry 
powder and kept at room temperature protected from light until use. 
Non-loaded SFNs were used in the experiments and considered as 
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controls. 
2.3. QSFN characterization and stability 
The characterization of the nanoparticles was performed using 
common techniques such as UV–Vis spectroscopy, Dynamic Light Scat-
tering (DLS), and Attenuated Total Reflectance Infrared Spectroscopy 
(ATR-FTIR), in order to verify the characteristics of the nanoparticles in 
terms of hydrodynamic size, protein conformation and quercetin 
loading, as previously described in more detail (Lozano-Pérez et al., 
2017). 
Briefly, the spectrophotometric quantification of the drug loading 
content (DLC) and encapsulation efficiency (EE) of quercetin were 
performed by using a Synergy MX UV–Vis spectrometer (BioTek In-
struments Inc; Winooski, VT, USA). The hydrodynamic characteristics of 
the QSFN, including mean diameter (Z-average), Polydispersity (PdI) 
and Zeta potential (ζ), were determined as described previously (Loz-
ano-Pérez et al., 2017) by DLS using a Malvern Zetasizer Nano ZSP 
(Malvern Instruments Ltd, Malvern, UK). 
Additionally, in order to confirm the suitability of the nanoparticles 
for the in vivo experiments, stability tests in different digestive fluids 
were performed. Briefly, 1 mg of QSFNs were suspended in 40 mL of 
Simulated Gastric Fluid (SGF) without pepsin (pH 1.2) prepared in 
accordance with the International Pharmacopeia methods (Lei et al., 
2020), and incubated at 37 ◦C for 2 h under mild agitation. After incu-
bation time, samples were neutralized with NaOH 0.1 M to pH 6.8. 
Unloaded SFNs were used as controls in the same conditions. 
2.4. Dextran sulphate sodium (DSS) model of mouse colitis 
This study was carried out in accordance with the ‘Guide of the Care 
and Use of Laboratory animals’ as promulgated by the National Institute 
of Health and the protocols approved by the Ethic committee of Labo-
ratory Animal of the University of Granada (Spain) (Ref. No. 17/09/ 
2019/156). Male C57BL/6J mice (7–9 weeks old) obtained from Janvier 
labs (St. Berthevin Cedex, France) were housed in makrolon cages, 
maintained in an air-conditioned atmosphere with a 12 h light/dark 
cycle and provided with free access to tap water. They were randomly 
assigned to five groups of 10 animals each. Colitis was induced by 
adding 3% w/v DSS (36–50 KDa, MP biomedicals, Ontario, USA) in the 
drinking water for 5 days. Mice were daily treated orally using an 
esophageal catheter with quercetin, SFNs or QSFNs at a dose of 5 mg of 
quercetin/kg in 200 μL of PBS solution. Non-colitic and non-treated DSS- 
colitic groups were included as reference and received PBS solution 
(200 μL/mouse/day). The treatments were maintained for three days 
after DSS removal, and then, mice were sacrificed. Every day, animal 
body weight, presence of gross blood in the faeces and stool consistency 
were individually evaluated in a blind manner. A score was assigned to 
each parameter according to a previously described criterion, which 
were used to calculate the average daily disease activity index (DAI) 
(Table 1) (Cooper et al., 1993). After sacrifice, the colon was aseptically 
removed, and the luminal content was collected. A representative piece 
of whole gut specimens (0.5 cm from the anus) was taken for histological 
studies. The remaining colonic tissue was minced, aliquoted and kept at 
− 80 ◦C until RNA isolation. 
2.5. Histological studies 
The gut specimen taken for histological studies was fixed in form-
aldehyde and embedded in paraffin. 5 µm sections were stained with 
haematoxylin and eosin (H&E), and alcian blue. The histological dam-
age was evaluated by a blinded pathologist observer, according to a 
previously reported histological score (Camuesco et al., 2012), taking 
into account presence of ulceration, infiltration, oedema and crypts 
condition. 
2.6. Analysis of gene expression by RT-qPCR 
TRIzol® Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) 
was used to extract total RNA from colon tissue following the manu-
facturer’s instructions. RNA was transcribed using olig(dT) primers 
(Promega, Southampton, UK), and the resulting cDNA (20 ng) was 
amplified on optical grade 48-plates in an EcoTM Real time PCR system 
(Illumina, San Diego, CA, USA) using KAPA SYBR® FAST qPCR Master 
Mix (Kapa Biosystems, Wilmington, MA, USA). The specific primers used 
for each gene are shown in Table 2. To normalize mRNA expression, the 
expression of the housekeeping gene glyceraldehyde 3-phosphate de-
hydrogenase (Gapdh) was measured for comparative reference. The 
relative gene expression was calculated using the 2-ΔΔCt method. 
2.7. Statistics 
Results are expressed as the mean ± SEM unless otherwise stated. 
Statistical analyses were performed using GraphPad Prism 7 software 
(Graph-Pad Software Inc., La Jolla, CA, USA) and SPSS Statistics 17.0 
Software Package (SPSS Inc., Chicago, IL, USA). Differences between 
means were tested for statistical significance using a one-way analysis of 
variance (ANOVA) and post hoc least significance tests. Non-parametric 
data (score) are expressed as the median (range) and were analysed 
using the Mann–Whitney U test. Differences between proportions were 
evaluated using the Chi-square test. Statistical significance was accepted 
at p < 0.05. 
3. Results 
3.1. Characterization of the nanoparticles 
The DLS measurements showed that QSFN used in this assay pre-
sented a monomodal nanometric size distribution (Zaverage = 175.8 ±
0.9 nm), low Polydispersity (PdI = 0.153 ± 0.009) and negatively 
Table 1 
Scoring of disease activity index (DAI).  
Score Weight loss Stool consistency Rectal bleeding 
0 None Normal Normal 
1 1–5%   
2 5–10% Loose stools  
3 10–20%   
4 > 20% Diarrhoea Gross bleeding 
DAI value is the combined scores of weight loss, stool consistency, and rectal 
bleeding divided by 3. Adapted from Cooper et al. (1993) (Cooper et al., 1993). 
Table 2 
Primer sequences and annealing temperatures used in real-time PCR assays in 
colonic tissue.  
Gene Organism Sequence 5′- 3′ Annealing T 
◦C 








IL-1β Mouse FW:TGATGAGAATGACCTCTTCT RV: 
CTTCTTCAAAGATGAAGGAAA 
55 
Il-6 Mouse FW: AGTCCTTCCTACCCCAATTTCC 
RV: TTGGTCCTTAGCCACTCCTTCC 
60 
iNOS Mouse FW:GTTGAAGACTGAGACTCTGG RV 
GACTAGGCTACTCCGTGGA 
56 
Mcp-1 Mouse FW:CAGCTGGGGACAGAATGGGG RV: 
GAGCTCTCTGGTACTCTTTTG 
62 
Nlrp3 Mouse FW: ATGCTGCTTCGACATCTCCT 
RV: AACCAATGCGAGATCCTGAC 
59 
Tnf-α Mouse FW: AACTAGTGGTGCCAGCCGAT 
RV: CTTCACAGAGCAATGACTCC 
60  
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charged surface (ζ = − 24.5 ± 4.1 mV) (see Table S1 and Figs. S1–S3 of 
the supplementary information file for details). 
The ATR-FTIR spectrum of QSFN, not only confirmed the presence of 
Q in the nanoparticles, but also the β-sheet conformation of the SF in the 
nanoparticles, which confers high stability in aqueous media (see 
Figs. S4 and S5 of the supplementary information file for details). 
QSFN also showed a DLC of 0.72 ± 0.09% (7.2 ± 0.9 μg/mg QSFN), 
representing a quercetin encapsulation efficiency of 18.12 ± 0.24%, 
which agrees with previous reports for these loading conditions (Fig. S6) 
(Lozano-Pérez et al., 2017). 
In order to use QSFN orally in vivo experiments, additional stability 
characterization tests were carried out. Thus, the stability tests per-
formed in the different digestive fluids confirmed the suitability of the 
nanoparticles for the in vivo experiments. QSFN dispersed in SGF 
without pepsin at pH 1.2, and incubated at 37 ◦C, presented a fast ag-
gregation due the protonation of the carboxylate groups of the aspartic 
and glutamic residues of the fibroin, showing a ζ = 3.62 ± 0.38 mV. 
Fig. 1 represents the evolution of the particle’s size and their aggregation 
along the experiment. Size increased from 175.8 ± 0.9 nm, when they 
were dispersed in ultrapure water at t = 0 min, to 1285 ± 93 nm at t = 5 
min, 1972 ± 144 nm at t = 10 min, 2408 ± 236 nm at t = 15 min, 
reaching 6697 ± 414 nm at t = 2 h of incubation time in the SGF (pH =
1.2). As it is known, ζ is another important parameter that directly af-
fects the stability of nanosuspension (Grumezescu, 2019). Thus, low 
values of ζ implies small repulsion forces among nanoparticles which 
lead to the formation of aggregates due to the high affinity of the sur-
faces of the nanoparticles. After raising the pH of the suspensions to 6.8, 
the size of the aggregates was reduced to 4366 ± 356 nm in comparison 
with the one at lower pH, although still bigger than in water. Interest-
ingly, the size distribution of the nanoparticles still showed their original 
characteristics even at pH higher than 7.5. SFNs, prepared as controls, 
displayed the same reversible aggregation profile after incubation in 
SGF at pH 1.2 and neutralization at pH 6.8. Thus, the presence of the 
quercetin did not affect aggregation or integrity of the nanoparticles 
3.2. Dextran sulphate sodium (DSS) model of mouse colitis 
Mice were given 3% DSS in drinking water which resulted in body 
weight loss, diarrhoea and presence of blood in the faeces. As a result, 
DAI values increased daily in control colitic mice during the course of 
the experiment. When the treated colitic mice were considered, only 
those mice administered QSFN showed significantly reduced DAI values 
at day 6 compared to the control colitic group as seen in Fig. 2. This 
beneficial effect was corroborated when the histological examination of 
the colonic specimens was performed (Fig. 3). DSS colitis is character-
ized by an important number of histological features, including mucosal 
erosions, mucin-depletion in the goblet cells, altered crypt architecture 
and intense inflammatory cell infiltration in the mucosa and lamina 
propria. Thus, untreated colitic mice exhibited marked unstructured 
lamina propria mucosa, greater distortion/damage to crypt architecture 
and severe inflammatory cell infiltration (Fig. 3C) in comparison to the 
non-colitic mice (Fig. 3B). However, SFN, Q and QSFN mice showed less 
severe pathological inflammation than the colitis control mice, and a 
partial recovery of the mucosa (Fig. 3D-F). However, only the QSFN 
treatment significantly improved tissue morphology, showing a signifi-
cant amelioration of the damage in the mucosal barrier, with the pres-
ence of goblet cells replenished with their mucin content, together with 
a reduction of the inflammatory cell infiltration (Fig. 3F). 
The intestinal inflammatory process induced by DSS was also asso-
ciated with an altered expression of different inflammatory markers. In 
fact, the colonic expression of the pro-inflammatory cytokines (Tnf-α, Il- 
1β and Il-6), the chemokine monocyte chemotactic protein-1 (Mcp-1), 
and the intracellular cellular adhesion molecule-1 (Icam-1) was signifi-
cantly increased in untreated colitic mice in comparison with non-colitic 
mice (Fig. 4). The administration of QSFN or SFNs to colitic mice 
significantly reduced the expression of Tnf-α, Il-1β and Il-6; however, 
only QSFN significantly lowered the expression of Mcp-1 or Icam-1 
(Fig. 4). Moreover, the colonic expression of the enzyme inducible nitric 
oxide synthase (iNos) was significantly upregulated in untreated colitic 
mice when compared to non-colitic mice and was only significantly 
reduced in those colitic mice treated with QSFN (Fig. 4). The DSS- 
induced colonic inflammation was associated with an increased 
expression of Nlrp3, one of the components of the inflammasome, and 
the administration of QSFN or quercetin to colitic mice showed a trend 
to decrease its expression, although no statistical differences were 
observed in comparison with untreated control colitic group (Fig. 4). 
4. Discussion 
Quercetin is a flavonoid ubiquitously found in nature in crude veg-
etables, foods and beverages, with interesting biological properties, like 
antioxidant and anti-inflammatory activities, which could be of poten-
tial use in the management of different human conditions (Ulusoy and 
Sanlier, 2020). Unfortunately, this therapeutic potential is conditioned 
by its low bioavailability after oral intake, due to low solubility and 
stability, being this is of special relevance in intestinal conditions, like 
IBD (Cai et al., 2013). In fact, previous preclinical studies have proposed 
that quercetin needs to be administered as a glycoside, like quercitrin or 
rutin, to show intestinal anti-inflammatory effects (Camuesco et al., 
2004; Comalada et al., 2005; Kwon et al., 2005; Mascaraque et al., 
2014). In an attempt to overcome these limitations, several strategies 
have been considered. Among these, different nanotechnology-based 
systems have been developed in order to obtain the delivery of natural 
Fig. 1. Size evolution of the particles and their aggregates along the experiment 
as a function of the pH of the media. Error bars represent standard deviation of 
the mean (n = 3). 
Fig. 2. Effects of QSFN treatment in DSS-induced colitis. Mice were exposed to 
3% DSS for 4 days, with the exception of one group (Non-colitic). Body weight 
loss and clinical score (DAI) are shown (n = 8 per group). Values are expressed 
as means ± SEM. Different letters are significantly different (p < 0.05). 
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antioxidants, including quercetin, thus improving its bioavailability and 
then, obtain a higher efficacy in clinical practice (Mukhopadhyay and 
Prajapati, 2015; Vaiserman et al., 2019). Therefore, the effects of pre-
viously characterized SFN loaded with quercetin (Lozano-Pérez et al., 
2017) were evaluated in the DSS experimental model of colitis in mice. 
The results obtained in this study have demonstrated the intestinal 
anti-inflammatory effects of QSFN in DSS colitis, improving the efficacy 
of the single components, both SFN and quercetin. This effect was evi-
denced in the course of the experiment, when DAI values were daily 
evaluated for each experimental group. DAI comprises different factors 
associated with intestinal inflammation, including weight loss, 
decreased stool consistency and blood in faeces, which are assumed to 
be the determinants of the severity of the DSS-induced intestinal in-
flammatory process (Hasannejad-Bibalan et al., 2020), similarly to 
human IBD. Moreover, the beneficial effect was also corroborated by the 
histological evaluation of the colonic samples. QSFN administration to 
colitic mice ameliorated the DSS-induced damage which included the 
preservation of the normal crypt architecture including the recovery of 
the mucin content of the goblet cells as well as a lower inflammatory cell 
infiltration in comparison with untreated colitic mice. On the contrary, 
colitic mice treated with quercetin or SFN did not show a significant 
beneficial effect when these parameters were considered. The significant 
histopathologic changes produced by QSFN could be associated with its 
intestinal anti-inflammatory effect. Actually, QSFN was able to reduce 
the colonic expression of different proinflammatory cytokines, probably 
as a result of the lower infiltration and activation of immune cells 
involved in the inflammatory response induced by the DSS. Besides, 
QSFN significantly reduced the colonic expression of the chemotactic 
protein Mcp-1 and the adhesion molecule Icam-1 in treated colitic mice, 
which have been reported to participate in lymphocyte migration to the 
inflamed tissue (Dotan et al., 2020). Of note, the infiltration of mono-
cytes in the damaged colonic tissue and the subsequent differentiation to 
macrophages seem to play a crucial role in the intestinal inflammatory 
response. Macrophage activation leads to production of different 
proinflammatory cytokines, including TNF-α, IL-1β and IL-6. TNF-α is 
considered a central mediator in intestinal inflammation that generates 
a cascade of intracellular events leading to the activation of death sig-
nals, mitogen activated protein kinases or transcription factors like NF- 
kB (Ruder et al., 2019). IL-1β can act in combination with TNF-α and IL- 
6 to increase the severity of inflammation (Mao et al., 2018). In 
Fig. 3. Relative histology score and representative H&E stained images per each group. Values are expressed as means ± SEM. Statistical significance among groups 
was evaluated by one-way ANOVA. Bars with a different letter differ statistically (p < 0.05). Arrows indicate crypts/regeneration of crypts (red), goblet cells (blue), 
epithelium surface erosion (black) and inflammatory cells infiltration (white). 
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particular, the binding of TNF-α and IL-1β to intestinal immune cells 
amplifies the immune response by enhancing T cell proliferation, pro-
moting leukocyte infiltration and facilitating cell–cell signalling (Neu-
ram, M.G., 2004). Interestingly, the inhibition of cytokine expression 
exerted by QSFN is similar to that obtained when SFN was administered 
to colitic mice, thus indicating that the carrier also contributed to lessen 
the intestinal inflammation, probably due to its antioxidant properties, 
and thus confirming our previous observations in other experimental 
models of colitis (Gou et al., 2019; Lozano-Pérez et al., 2017; Lozano- 
Pérez et al., 2014; Rodriguez-Nogales et al., 2016). On the contrary, the 
oral administration of quercetin was devoid of any significant effect on 
all these biochemical markers, thus confirming the absence of intestinal 
anti-inflammatory effect of the aglycone previously reported (Kwon 
et al., 2005). These results support those obtained in the histological 
evaluations. Finally, IL-6 is a mediator of the acute phase response and T 
cell differentiation, activation and resistance against apoptosis (Tanaka 
et al., 2014; Waldner and Neurath, 2014) as well as participates on the 
onset of inflammation in colitis (Mitsuyama et al., 1995; Wine et al., 
2013). Our results indicated that QSFN and SFN supplementation 
restored significantly the expression of Il-6, however, quercetin did not 
show significant changes in its expression. Considering all these, it is 
obvious that the carrier has a positive impact on the inflammatory 
process. These results may be relevant since the expression of these 
proinflammatory cytokines has been described to be increased in human 
IBD, and the effect of these cytokines on the intestine has been directly 
related to the induction of tissue injury and/or destruction (León et al., 
2009). 
In addition, NLRP3 inflammasome has been proposed as a crucial 
regulator of intestinal homeostasis, and it has been implicated in the 
pathogenesis of IBD through the production of pro-inflammatory cyto-
kines, including IL-1β (Zhen and Zhang, 2019). Thus, colonic inflam-
mation was associated with increased expression of Nlrp3, which was 
significantly ameliorated after administration of QSFN to colitic mice. 
Previous in vitro and in vivo studies have shown the ability of quercetin to 
inhibit NLRP3 inflammasome activation in different experimental con-
ditions (Domiciano et al., 2017; Xue et al., 2017). However, in the 
present study, quercetin administration to colitic mice only showed a 
significant trend to decrease the colonic expression of Nlrp3 when is 
loaded in the nanoparticles, which would support the fact that quercetin 
needs its incorporation into SFN to exert an intestinal anti-inflammatory 
effect. 
Finally, overproduction of NO is a feature of intestinal inflammation 
that correlates with the severity of the symptoms in IBD patients 
(Kamalian et al., 2020). The main source of NO in these inflammatory 
conditions is the iNOS enzyme, whose expression is upregulated by 
proinflammatory cytokines and different immunogenic stimuli. The 
activation of iNOS and the subsequent overproduction of NO facilitate 
the amplification of the inflammatory response by chemotaxis of neu-
trophils, natural killer cells and macrophages. Moreover, in an inflam-
matory environment there is oxidative stress with excessive production 
of reactive oxygen species, and nitric oxide can react with superoxide 
anions to promote the production of reactive nitric oxygen species, 
which act as cytotoxic agents contributing to perpetuate mucosal injury 
and inflammation (Kolios et al., 2004). When colonic iNOS expression 
Fig. 4. Biochemical evaluation of the effects of QSFN treatment; mRNA expression of different mediators; Tnf-α, Il-6, Il-1β, Mcp-1, Icam-1, iNos, Nlrp3, was quantified 
by real-time PCR, and fold changes are expressed as means ± SEM. Statistical significance among groups was evaluated by one-way ANOVA. Bars with different 
letters are significantly different (p < 0.05). 
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was evaluated in colitic mice, only those receiving QSFN showed a 
significant reduction in comparison with control colitic mice, thus 
contributing to its intestinal anti-inflammatory effect. It is important to 
note that, although flavonoids have been reported to modulate nitric 
oxide pathways that would justify their beneficial effects against in-
flammatory conditions (Kamalian et al., 2020), the oral administration 
of quercetin to colitic mice did not result in a significant reduction of the 
expression of iNOS, thus confirming the key role that the carrier SFN 
may play in the beneficial effects observed in the present study. 
5. Conclusion 
The treatment with QSFN has displayed intestinal anti-inflammatory 
properties in the DSS model of colitis in mice. Taking into account the 
results, it could constitute an attractive and innovative strategy for the 
management of the inflammatory bowel conditions, even more consid-
ering that it overcomes the low bioavailability of quercetin due their 
solubility properties, which restrains its use in clinical practice. These 
results reinforce the previous knowledge about the ability of the silk 
fibroin nanoparticles acting as an bioactive carrier for different natural 
molecules, displaying antioxidant and anti-inflammatory properties, 
which supports their future application in nanomedicine. 
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Tripodo, G., Prina-Mello, A., Torre, M.L., 2019. Silk fibroin nanoparticles for 
celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities 
in an in vitro model of osteoarthritis. Eur. J. Pharm. Biopharm. 137, 37–45. 
Crivelli, B., Perteghella, S., Bari, E., Sorrenti, M., Tripodo, G., Chlapanidas, T., Torre, M. 
L., 2018. Silk nanoparticles: from inert supports to bioactive natural carriers for drug 
delivery. Soft Matter 14 (4), 546–557. 
de Souza, H.S.P., Fiocchi, C., Iliopoulos, D., 2017. The IBD interactome: an integrated 
view of aetiology, pathogenesis and therapy. Nat. Rev. Gastroenterol. Hepatol. 14 
(12), 739–749. 
Davoudi, Z., Peroutka-Bigus, N., Bellaire, B., Jergens, A., Wannemuehler, M., Wang, Q., 
2021. Gut organoid as a new platform to study alginate and chitosan mediated PLGA 
nanoparticles for drug delivery. Mar. Drugs 19 (5), 282. https://doi.org/10.3390/ 
md19050282. 
Domiciano, T.P., Wakita, D., Jones, H.D., Crother, T.R., Verri, W.A., Arditi, M., 
Shimada, K., 2017. Quercetin inhibits inflammasome activation by interfering with 
ASC oligomerization and prevents interleukin-1 mediated mouse vasculitis. Sci. Rep. 
7 (1) https://doi.org/10.1038/srep41539. 
Dong, Y., Lei, J., Zhang, B., 2020. Dietary quercetin alleviated DSS-induced colitis in 
mice through several possible pathways by transcriptome analysis. Curr. Pharm. 
Biotechnol. 21 (15), 1666–1673. 
Dotan, I., Allez, M., Danese, S., Keir, M., Tole, S., McBride, J., 2020. The role of integrins 
in the pathogenesis of inflammatory bowel disease: Approved and investigational 
anti-integrin therapies. Med Res Rev. 40 (1), 245–262. 
Filipe-Ribeiro, L., Cosme, F., Nunes, F.M., 2018. Data on changes in red wine phenolic 
compounds and headspace aroma compounds after treatment of red wines with 
chitosans with different structures. Data Brief. 17, 1201–1217. 
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